Hoth Therapeutics’ (HOTH) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a research note released on Tuesday morning,Benzinga reports. The brokerage currently has a $5.00 price target on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $4.00 price target on shares of Hoth Therapeutics in a research report on Thursday, January 23rd.

Hoth Therapeutics Stock Up 42.5 %

Shares of HOTH stock opened at $1.24 on Tuesday. The stock has a 50-day simple moving average of $1.19 and a 200 day simple moving average of $0.98. Hoth Therapeutics has a fifty-two week low of $0.58 and a fifty-two week high of $3.80. The stock has a market capitalization of $8.56 million, a P/E ratio of -0.94 and a beta of 0.80.

Institutional Investors Weigh In On Hoth Therapeutics

A hedge fund recently bought a new stake in Hoth Therapeutics stock. Virtu Financial LLC bought a new position in Hoth Therapeutics, Inc. (NASDAQ:HOTH) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics as of its most recent filing with the Securities and Exchange Commission. 7.08% of the stock is owned by hedge funds and other institutional investors.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.